1. Chukwuma, UJ, Arinze, NM, Thaddeus, ON, et al. The histological subtypes of breast cancer seen in a tertiary hospital in South-East, Nigeria. Glob J Health Sci 2020; 12(6): 93–105.
Google Scholar | Crossref2. Nzegwu, M, Uzoigwe, J, Omotowo, B, et al. Predictive and prognostic relevance of immunohistochemical testing of estrogen and progesterone receptors in breast cancer in South East Nigeria: a review of 417 cases. Rare Tumors 2021; 13: 20363613211006338.
Google Scholar | SAGE Journals3. Wright, N, Rida, P, Rakha, E, et al. Panoptic overview of triple-negative breast cancer in Nigeria: current challenges and promising global initiatives. J Glob Oncol 2018; 4: 1–20.
Google Scholar | Medline4. Kuiper, GG, Enmark, E, Pelto-Huikko, M, et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93(12): 5925–5930.
Google Scholar | Crossref | Medline | ISI5. Mosselman, S, Polman, J, Dijkema, R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49–53.
Google Scholar | Crossref | Medline | ISI6. Speirs, V, Skliris, GP, Burdall, SE, et al. Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol 2002; 55: 371–374.
Google Scholar | Crossref | Medline | ISI7. Skliris, GP, Leygue, E, Watson, PH, et al. Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol 2008; 109(1–2): 1–10.
Google Scholar | Crossref | Medline8. Marotti, JD, Collins, LC, Hu, R, et al. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol 2010; 23: 197–204.
Google Scholar | Crossref | Medline9. Palmieri, C, Cheng, GJ, Saji, S, et al. Estrogen receptor beta in breast cancer. Endocr Relat Cancer 2002; 9: 1–13.
Google Scholar | Crossref | Medline10. Leygue, E, Murphy, LC. A bi-faceted role of estrogen receptor β in breast cancer. Endocr Relat Cancer 2013; 20: R127–R139.
Google Scholar | Crossref | Medline11. Badve, SS, Gökmen-Polar, Y. TP53 status and estrogen receptor-beta in triple-negative breast cancer: company matters. J Natl Cancer Inst 2019; 111(11): 1118–1119.
Google Scholar | Crossref | Medline12. Mukhopadhyay, UK, Oturkar, CC, Adams, C, et al. TP53 status as a determinant of proversus anti-tumorigenic effects of estrogen receptor-beta in breast cancer. J Natl Cancer Inst 2019; 11: djz051.
Google Scholar13. Gruvberger-Saal, SK, Bendahl, PO, Saal, LH, et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 2007; 13(7): 1987–1994.
Google Scholar | Crossref | Medline | ISI14. Honma, N, Horii, R, Iwase, T, et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008; 26: 3727–3734.
Google Scholar | Crossref | Medline | ISI15. Yan, Y, Li, X, Blanchard, A, et al. Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC). Ann Oncol 2013; 24(8): 1986–1993.
Google Scholar | Crossref | Medline | ISI16. Goel, AK, Nandy, M, Sharma, G. Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: exciting early results. Indian J Med Paediatr Oncol 2010; 31(3): 76–78.
Google Scholar | Crossref | Medline17. Comen, EA, Robson, M. Poly(adp-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J 2010; 16: 48–52.
Google Scholar | Crossref | Medline18. Ryan, PD, Tung, NM, Isakoff, SJ, et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J Clin Oncol 2009; 27(15): 551–551.
Google Scholar | Crossref